Inclusion Criteria:

1. 18 to 60 years of age

2. patients had histologically or cytologically confirmed solid tumors that was
refractory to standard therapy.

3. life expectancy of at least 3 months.

4. ECOGPS ≤ 1

5. Adequate hematologic, renal, and hepatic function was required as determined by the
following: WBC ≥4×109/L, absolute neutrophil count ≥ 1.5×109/L, platelet count
≥100×109/L, hemoglobin ≥ 9g/dL, total bilirubin ≤1.5 upper limit of normal [ULN],AST
≤ 2.5 ULN, or ≤ 5 ULN if there was evidence of liver metastases; alkaline
phosphatase ≤ 2.5 ULN, or ≤ 5 ULN if there was evidence of liver Metastases;
creatinine clearance ≥50 mL/min.

Exclusion Criteria:

1. Pregnant and latent women, no contraception for women of childbearing age

2. Have taken other treatments

3. Be allergic to endostatin and other ingredient

4. Gastrointestinal Hemorrhage

5. Have Participated any clinical trail during the last 4 week

6. ECG: QTC ≥ 480 ms

7. patients had clinically apparent CNS disease ( primary brain tumors, tumor related
apoplexy, CNS metastases, carcinomatous meningitis.)

8. Cardiovascular and mental disease

9. HIV-1 infected

10. HBV, HBV infected ,Hepatitis B surface antigen positive

11. Patients on therapeutic doses of heparin or antiplatelet agents.